CAMBRIDGE, Mass., Oct. 1, 2024
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq:
NRBO), a clinical-stage biotechnology company focused on
transforming cardiometabolic diseases, today announced that
management will participate in the following investor conferences
in October:
- October 7: H.C. Wainwright
8th Annual MASH Virtual Conference. Hyung Heon Kim, President and Chief Executive
Officer, will present a company overview on Monday, October 7, at 11:00 am ET.
Management will also be available for one-on-one meetings during
the event. Individuals who would like to listen to the Company's
presentation or request a meeting can do so after registering for
the conference at https://hcwevents.com/mashconference/.
- October 15-17: 2024 Maxim
Healthcare Virtual Summit. Mr. Kim and Marshall H. Woodworth, Chief Financial Officer,
will participate in a virtual fireside chat hosted by Jason McCarthy, Ph.D., senior managing director,
head of biotechnology research at Maxim Group, on Tuesday, October 15, at 2:30 pm ET.
To schedule a meeting with management outside of these
conferences, investors can contact Michael
Miller at mmiller@rxir.com.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals,
Inc. is a clinical-stage biotechnology company focused on
transforming cardiometabolic diseases. The company is currently
developing DA-1726 for the treatment of obesity, and is developing
DA-1241 for the treatment of Metabolic Dysfunction-Associated
Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM)
analogue that functions as a glucagon-like peptide-1 receptor
(GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a
naturally-occurring gut hormone that activates GLP1R and GCGR,
thereby decreasing food intake while increasing energy expenditure,
thus potentially resulting in superior body weight loss compared to
selective GLP1R agonists. DA-1241 is a novel G-protein-coupled
receptor 119 (GPR119) agonist that promotes the release of key gut
peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241
demonstrated a positive effect on liver inflammation, lipid
metabolism, weight loss, and glucose metabolism, reducing hepatic
steatosis, hepatic inflammation, and liver fibrosis, while also
improving glucose control.
For more information, please
visit www.neurobopharma.com.
Contacts:
NeuroBo Pharmaceuticals
Marshall
H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@neurobopharma.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-to-participate-in-investor-conferences-in-october-302263743.html
SOURCE NeuroBo Pharmaceuticals, Inc.